Hemodynamically unstable or at-risk critically ill patients often face organ dysfunction, multi-organ failure, and death due to causes such as hypovolemia, cardiac dysfunction, or vasomotor dysfunction. To address these issues, early hemodynamic management through techniques such as fluid therapy and vasoactive drug administration is crucial in maintaining organ perfusion and oxygen delivery. This is known as perioperative goal-directed therapy, which aims to balance the supply of oxygen via cardiac output with the consumption of oxygen by the organs. Monitoring and treating hemodynamic variables through a hemodynamic monitoring system helps to achieve this balance.
Hemodynamic monitoring systems market report shows that thermodilution techniques are widely considered the best method for hemodynamic monitoring, but their invasiveness – which involves the insertion of arterial and/or central venous catheters – is being challenged by newer non-invasive hemodynamic monitoring techniques. Despite their status as the gold standard, thermodilution monitors can cause mechanical, thrombotic, and infectious complications, and a less invasive approach may be preferred in certain situations. This is especially true for high-risk surgery patients and those with multiple comorbidities, as well as morbidly obese and elderly patients for whom an arterial catheter would pose additional risks. Beat-to-beat arterial pressure analysis measured through thermodilution techniques is still often necessary.
As an alternative to more invasive techniques, new non-invasive hemodynamic monitoring systems are gaining popularity. These include transthoracic echocardiography, thoracic electrical bio-impedance, pulse contour systems, estimated continuous cardiac output, and ultrasonic cardiac output monitoring. These devices can measure the same parameters as their invasive counterparts but rely on computer software and algorithms to calculate the results. As demand for these non-invasive options grows, they are driving the development of new products in this field. The global hemodynamic monitoring systems market is projected to grow at a CAGR of 5.4% to reach US $2,500M by 2033, from an estimated USD $1,470 M in 2022. The hemodynamic monitoring systems market report reveals these key factors which will influence the future growth of the market:
- The hemodynamic monitoring system disposable sensors segment is projected to become the largest segment by 2024 due to an increased number of major surgeries
- Non-invasive devices will continue to be the fasted growing segment; the future of hemodynamic monitoring is expected to be driven by this segment
- Asia Pacific is expected to be the fastest growing region, India accounts for 43% share in the South Asian market in 2023.
The non-invasive hemodynamic monitoring is expected to drive the future of hemodynamic monitoring. The current market for non-invasive hemodynamic monitoring is highly competitive due to the constant development of new products and technological advances by existing and expanding manufacturers. In addition, acquisitions of emerging innovative non-invasive hemodynamic monitoring system developers and manufacturers are expected to increase as larger companies look to add to their product portfolios. While this provides a profitable exit strategy, it is important for prospective market entrants to seek expert life science consultancy and medical device consultants for the market analysis of medical devices early in the development phase. A quick overview of seven non-invasive and minimally invasive market players and their hemodynamic devices is provided in the table below:
|Baxter International Inc.|
Newton Center, MA
|· CHEETAH NICOM Starling SV||· Non-invasive continuous monitoring in various care settings (ED, OR, ICU)|
· Dynamic assessment reports showing SVI changes in response to fluid challenges and Frank-Starling curve position
· Utilizes small electric current applied through four pads placed near heart
|Deltex Medical Group Plc.|
|· TrueVue ODM+||· Minimally-invasive disposable probe for directly measuring central blood flow|
· Doppler ultrasound probe placed in the esophagus to measure flow velocity in the descending aorta
· Used to guide >10% change in stroke volume optimization (SVO)
|· ClearSight – Hemodynamic monitor||· Utilizes Nexfin non-invasive technology with a volume clamp on the finger|
· Counter pressure from a bladder inside the cuff is adjusted 1000 times per second to maintain constant arterial volume
· Edwards acquired ClearSight from BMEYE (Netherlands) in 2012, expanding their offerings to include non-invasive hemodynamic monitoring
· Edwards is a leader in minimally invasive hemodynamic monitoring, with products such as FloTraq and VolumeView systems
|ICU Medical, Inc.|
San Clemente, CA
|· LiDCO LXi Non-invasive Q2 Plus||· Cogent accepts both invasive and minimally-invasive inputs, which are displayed on a mobile hemodynamic monitor|
· LiDCO LXi Non-invasive uses a dual finger oscillometric cuff for continuous monitoring
· In 2016, LiDCO Group reached a US distribution agreement with ICU medical for LXi
· Q2 Plus is an invasive device that utilizes a pulmonary artery catheter
|LiDCO Group plc|
|· Standard hemodynamic monitor is minimally-invasive|
· Option to add non-invasive continuous hemodynamic monitoring capabilities
· Offers both a fixed annual fee for treating an unlimited number of patients and a per-patient plan
|· MightySat Rx|
· Patient SafetyNet
|· Noninvasive hemodynamic devices utilize wireless signal extraction technology|
· MightyStat Rx is a fingertip pulse oximeter with a screen on the clamp
· Patient SafetyNet is a remote monitoring and clinician notification system
· Radius-7 device can be worn untethered without the need to disconnect the patient
|Osypka Medical GmbH|
|· AESCULON is a continuous, non-invasive hemodynamic monitor with an oscillometric BP monitor|
· ICON hemodynamic monitor is non-invasive and offers a portable, battery-operated monitor
· Both monitors use electrical cardiometry with software for data capture and storage.
The market for non-invasive hemodynamic devices has been driven by several factors, according to medical device market research. One major factor is the rising prevalence of chronic illnesses, such as cardiovascular and respiratory diseases, which have led to an increase in demand for non-invasive hemodynamic devices. These devices offer a more convenient and comfortable option for frequent monitoring and treatment, which is often required by individuals with chronic conditions. The growing elderly population, who are more at risk of chronic illnesses and complications from invasive procedures, has also contributed to the demand for non-invasive hemodynamic devices. Additionally, the expansion of markets in Asia has led to improved regional distribution channels, which will continue to drive the market for non-invasive hemodynamic devices. The development of non-invasive technology for early detection of shock and sepsis is also anticipated to further boost the market. Companies seeking to enter the hemodynamic monitoring market should consider consulting experts early in the development phase to fully understand market opportunities and competitive landscapes.